XUNFEIHEALTH (HKEX: 02506) has announced the signing of a strategic cooperation memorandum of understanding with PT DSST Mas Gemilang, dated June 9, 2026.

This memorandum outlines the intention of both parties to forge a long-term strategic partnership. The collaboration aims to leverage XUNFEIHEALTH's expertise in artificial intelligence healthcare technology alongside the partner's digital infrastructure, investment capabilities, and local market resources in Indonesia.

The primary objectives of this alliance are threefold: to accelerate the deployment of AI solutions within Indonesia's healthcare system; to support priority public health projects initiated by the Indonesian government; and to explore joint investment, co-development, and commercialization opportunities in the digital health sector across Indonesia and Southeast Asia.

Company Background and Strategic Rationale

XUNFEIHEALTH is a leading player in China's AI healthcare sector, with a mission to serve as an AI diagnostic assistant for medical professionals and a personal AI health aide for individuals. The company maintains its leadership in medical large language models through continuous technological development and the construction of extensive medical knowledge bases, offering a suite of products designed to empower government agencies, hospitals, and patients.

PT DSST Mas Gemilang is an investment holding platform registered in Indonesia, focusing on the digital infrastructure and technology sectors. It is a member of the Sinar Mas Group, and its parent company, PT Dian Swastatika Sentosa Tbk, is listed on the Indonesia Stock Exchange (IDX: DSSA). Public information indicates the partner manages a diversified portfolio, including data centers, IT solutions, and e-wallet services, with a commitment to building Indonesia's digital economic infrastructure.

Board's Perspective on the Partnership

The company's board believes entering into this memorandum is in the best interests of XUNFEIHEALTH and its shareholders. Southeast Asia represents one of the world's fastest-growing regions for digital healthcare demand. This partnership allows the company to utilize its world-class AI medical technology, combined with the partner's investment strength and local market access, to accelerate its entry into Indonesia—its first key overseas market—in a localized and compliant manner. This initiative is expected to lay a solid foundation for future joint investments, product co-development, and commercialization efforts, thereby advancing the company's internationalization strategy.